Thryv Therapeutics to Participate at the Piper Sandler Spring Biopharma Symposium

Press Releases
Written By Thryv Therapeutics

Montreal, Quebec – April 10, 2024 – Thryv Therapeutics is pleased to announce that it will be hosting investor meetings at the Piper Sandler Spring Biopharma Symposium on Tuesday, April 16, 2024, at the Encore Boston Harbor.

To schedule a 1x1 meeting with Thryv Therapeutics, email corporateaccess@psc.com.

About Thryv Therapeutics Inc.

Thryv Therapeutics Inc. is a privately owned company based in Montreal, Quebec, Canada. Thryv Therapeutics is pioneering a precision medicine approach to treat indications including Congenital Long QT Syndromes (LQTS), atrial fibrillation and heart failure, with potent and selective inhibitors of Serum Glucocorticoid inducible Kinase (SGK1). For more information, please visit www.thryvtrx.com.

Media Inquiries

daphne@thryvtrx.com | 514 973 0915

Thryv Therapeutics
Previous

Thryv Therapeutics to Present Preclinical Data of SGK1 Inhibition in Models of Drug-Induced QT Prolongation at the 2024 Heart Rhythm Society Meeting
Next

Thryv Therapeutics to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference